Journals / Anadolu Kardiyoloji Dergisi / 2007 / Cilt: 7 - Sayı: 1

Diltiazem ve metoprololün nonvalvüler kronik atriyal fibrilasyon olan hastalarda sol atriyal apendiks üzerine etkileri

Effect of diltiazem and metoprolol on left atrial appendix functions in patients with nonvalvular chronic atrial fibrillation

Pages
37–41
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: In patients with CAF metoprolol used for ventricular rate control had no effect on LAA flow velocity and the observed decrease in LAA flow rate velocity with intravenous diltiazem was insignificant.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Thrombo-embolic events are the important cause of mortality and morbidity in patients with chronic atrial fibrillation (CAF).
📊
Key Findings & Data:Flow rate velocity (FRV) inside the LAA is the major determinant of thrombus formation.
💡
Conclusion & Impact:Conclusions: In patients with CAF metoprolol used for ventricular rate control had no effect on LAA flow velocity and the observed decrease in LAA flow rate velocity with intravenous diltiazem was insignificant.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Thrombo-embolic events are the important cause of mortality and morbidity in patients with chronic atrial fibrillation (CAF). The origin of thromboembolism is often the left atrial appendix (LAA). Flow rate velocity (FRV) inside the LAA is the major determinant of thrombus formation. The aim of our study was to investigate the effects of diltiazem and metoprolol used for ventricular rate control on FRV of the LAA in CAF patients and thus to evaluate the positive or negative effects of these two drugs on thromboembolic events. Methods: Sixty-four patients were included in the study. All patients were suffering from CAF for more than a year. The patients were allocated to two groups according with agent used for rate control - metoprolol (Group 1; n=31) and diltiazem (Group 2; n=33). Transesophageal echocardiography was applied to all patients and LAA FRV was measured by a pulse wave Doppler in the 1/3 proximal portion of the LAA. The measurements were repeated after applying 5 mg metoprolol to Group 1 and 25 mg diltiazem to Group 2 via venous cannula. Results: In Group 1 after metoprolol LAA flow velocity changed from 0.25 ± 0.90 m/s to 0.25 ± 0.10 m/s (p>0.05). In group 2 after diltiazem left atrial appendix FRV decreased from 0.21 ± 0.9 m/s to 0.19 ± 0.6 m/s (p>0.05). Conclusions: In patients with CAF metoprolol used for ventricular rate control had no effect on LAA flow velocity and the observed decrease in LAA flow rate velocity with intravenous diltiazem was insignificant.

Özet

Amaç: Kronik atriyal fibrilasyonlu (AF) hastalarda, tromboembolik olaylar önemli bir mortalite ve morbidite nedenidir. Tromboembolinin kaynağı sıklıkla sol atriyal apendiksdir. Sol atriyal apendiks içindeki akım hızı (boşalma hızı) trombus oluşumu için major belirleyicidir. Çalışmamızda kronik AF’u olan hastalarda hız kontrolünde kullanılan metoprolol ve diltiazemin akut uygulanması ile sol atriyal apendiks (SAA) akım hızlarında (boşalma hızı) ne gibi değişikler yaptığı ve ventrikül hızının kontrolünde kullanılan bu iki ilacın trombo-embolik olaylar üzerine olumlu veya olumsuz etkisini irdelemekti. Yöntemler: Çalışmaya son bir yıldır kronik AF tanısı almış 64 hasta alındı. Vakalar rasgele grup 1 ve grup 2 olmak üzere 2 gruba ayrıldı. Grup 1; toplam 31 vakadan oluşuyordu, grup 2’de ise toplam 33 vaka mevcut idi. Tüm hastalara transözofajiyal ekokardiyografi uygulanarak sol atriyal apendiks görüntülendi. Apendiks’in 1/3 proksimaline pulse wave Doppler uygulanarak, akım hızı ölçüldü. Grup 1’e metoprolol 5 mg, Grup 2’ye ise diltiazem 25 mg, venöz kanül aracılığı ile uygulandıktan sonra ölçümler tekrarlandı. Bulgular: Sol atriyal apendiks akım hızı Grup 1’de metoprolol sonrası 0.25 ± 0.9 m/sn’den 0.25 ± 0.10 m/sn’e (p>0.05), grup 2’de ise diltiazem sonrası LAA akım hızı ise, 0.21 ± 0.9 m/sn den 0.19 ± 0.6 m/sn değişim gösterdi (p>0.05). Sonuç: Kronik atriyal fibrilasyonlu hastalarda, ventrikül hızının kontrolünde kullanılan intravenöz metoprolol’ün SAA akım hızına etkisi olmadığını ve diltiazemin sol atriyal apendiks akım hızında anlamlı olmayan azalmasına yol açtığını gösterdik.

🔖

Cite This Article

COŞKUN, N., İLKAY, E., KARACA, I., AKBULUT, M., ARSLAN, N., YAVUZKIR, M., DAĞLI, N., IŞIK, A., BALİN, M. (2022). Diltiazem ve metoprololün nonvalvüler kronik atriyal fibrilasyon olan hastalarda sol atriyal apendiks üzerine etkileri. Anadolu Kardiyoloji Dergisi, Cilt: 7 - Sayı: 1, 37–41. https://ajindex.com/articles/437221

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Lip GYH, DiMarco JP. Supraventricular arrhythmias. In Crawford MH, DiMarco JP editors: Cardiology. London: Mosby; 2001. p.4.10.1-18. 2.Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation. The Framingham Study.N Engl J Med 1982;306:1018-22. 3. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation. Circulation 1996; 93: 1262-77. 4. Olgin JE, Zipes DP. Specific arrhythmias. Diagnosis and Treatment. In: Braunwald E, Zıpes DP, Libby P, editors. Heart Disease 6th edition. Philadelphia: W.B. Saunders Company; 2001. p. 815-89. 5. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med 1995; 98: 476-84. 6. Fatkin D, Kelly RP, Feneley MD. Relations between left atrial appendage blood flow velocity, spontaneous echo contrast and thromboembolic risk in vivo. J.Am Coll Cardiol 1994; 23: 961-9. 7. Mugge A, Kuhn H, Nikutta P, Grote J, Lopez JA, Daniel WG. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994; 23: 599-607. 8. Man-Son-Hing M, Laupacis A, O'Connor AM, Biggs J, Drake E, Yetisir E, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA 1999; 282: 737-43. 9. Brignole M, Menozzi C. Control of rapid heart rate in patients with atrial fibrillation: drug or ablation? Pacing Clin Electrophysiol 1996; 19: 348-56. 10. Atwood JE, Sullivan M, Forbes S, Myers J, Pewen W, Olson HG, et al. Effect of beta- adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987; 10: 314-20. 11. Lundstöm T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation:effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86-90. 12. Segal JB, Mcnamara RL, Miller MR, Kim N, Goodman SN, Powe NR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000; 49: 47-59. 13. Waldo AL, Van Wagoner DR. Atrial fibrillation: In: Spooner PM, Rosen MR, editors. Foundations of Cardiac Arrhythmias. Basic Concepts and Clinical Approaches. New York; Marcel Dekker Inc: 2001; pp. 479